---
title: "Retension Pharmaceuticals tumbles 8% during regular trading"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/304520054.md"
description: "Retension Pharmaceuticals fell 8.15% to US$10.65. Down 30.65% over ten sessions and down 10.42% from IPO price."
datetime: "2026-11-05T20:24:22.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/304520054.md)
  - [en](https://longbridge.com/en/news/304520054.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/304520054.md)
generator: "portal-rs"
---

# Retension Pharmaceuticals tumbles 8% during regular trading

Retension Pharmaceuticals (RTSN.US) tumbled more than **8%** during regular trading to **$10.65**.

The stock is down 30.65% over the past ten sessions and down 10.42% from its IPO price. It sits 42.86% below its 52-week high of US$18.64.

The Nasdaq Composite is down 6.69% over the past five sessions and up 5.12% year to date.

The biotechnology industry index fell 3.7% over the same period.

Based on public media reports. AI-generated; not investment advice.

### Related Stocks

- [RTSN.US](https://longbridge.com/en/quote/RTSN.US.md)

## Related News & Research

- [Retension Pharma director Franklin M. Berger acquires 10,000 common shares for $120,000](https://longbridge.com/en/news/301760599.md)
- [Retension Pharmaceuticals adopts amended and restated bylaws ahead of IPO close](https://longbridge.com/en/news/301750965.md)
- [Anthropic’s Valuation Target Has Slipped From $2 Trillion to Under $1.5 Trillion. Here’s Why](https://longbridge.com/en/news/305493732.md)
- [MaxLinear Stock In Focus After New AI Optics Power Chip Launch](https://longbridge.com/en/news/305513238.md)
- [Visa says card enumeration fuels more than $1 billion in annual global fraud losses](https://longbridge.com/en/news/305494235.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**